The Monkeypox Testing Market Size was valued at USD 1.73 billion in 2023 and is expected to reach USD 2.58 billion by 2032 and grow at a CAGR of 4.55% over the forecast period 2024-2032. This report presents the uptake rate of monkeypox testing by region, dictated by public health activity and government response measures. Reimbursement policy and insurance cover are considered in the research, which is the main determinants of accessibility of the market, as well as the changing regulatory environment and approval patterns impacting test availability. Moreover, it delves into the latest breakthroughs in monkeypox diagnosis, such as rapid and molecular testing advancements, and the increasing trend towards point-of-care (PoC) testing compared to conventional laboratory techniques. The report also evaluates government, commercial, private, and out-of-pocket healthcare expenditures on monkeypox testing, reflecting regional variations in market trends and investment.
The U.S. Monkeypox Testing Market grew at a CAGR of 5.75% over the forecast period 2024-2032. In the United States, expanded federal funding and CDC-driven efforts have fueled test availability, as commercial labs and public health networks boosted diagnostic capacity to meet growing demand.
Drivers
The monkeypox testing market is driven by rising global monkeypox cases, increased government funding, and advancements in diagnostic technologies.
The 2022 worldwide monkeypox pandemic prompted increased attention and monitoring, pushing the pace of demand for speedy and precise testing. There were more than 85,000 confirmed instances reported by the WHO in 110 nations, reinforcing the requirement for extensive diagnostics with speed. Governments around the world invested enormous sums; e.g., the United States Department of Health and Human Services (HHS) put USD 140 million towards strengthening testing facilities. Technological advancements in PCR and LFA have accelerated detection speed and precision, enhancing accessibility for testing. The increasing focus on PoCT has further increased market growth, with organizations creating portable and affordable rapid tests. Regulatory approvals for monkeypox diagnostic kits have also increased—the FDA approved more than 20 emergency-use diagnostic kits in 2023 alone. Growth through more public-private collaborations and partnerships between healthcare organizations and diagnostic firms is also driving market growth. Increased awareness initiatives and compulsory testing protocols in risk areas have urged people to increase tests. The surge in demand from hospitals, diagnostics laboratories, and public health centers has positioned the monkeypox testing market to witness constant growth, coupled with continuous research efforts in CRISPR-based and AI-assisted diagnostic platforms.
Restraints
The market faces high costs of PCR-based testing, limited accessibility in low-income regions, and stringent regulatory requirements.
The most precise diagnostic tests, PCR tests, are costly, priced between USD 100 and USD 300 per test, rendering them inaccessible in most areas. The use of cold-chain logistics and advanced laboratory facilities further restrains the reach of rural and less developed regions. Regulatory obstacles also slow down market growth. Diagnostic firms need to comply with stringent FDA, EMA, and WHO approval procedures, holding back the launch of new testing kits. Numerous rapid antigen-based tests, for instance, were held up over fears of decreased sensitivity relative to PCR. Compliance adds to costs for manufacturers, slowing down innovation. Furthermore, low awareness and stigma surrounding monkeypox have led to underreporting and reduced testing levels, especially in developing countries. Social discrimination is a major reason why many individuals shun testing, especially where monkeypox is erroneously linked to certain groups. The reliance on central laboratory testing further inhibits market penetration. Access to high-level diagnostic infrastructure exists in only 30% of global healthcare facilities, constraining rapid detection and response activities. In the absence of significant government interventions and policy reforms, accessibility of testing will continue to pose a hindrance to market growth.
Opportunities
The rising demand for point-of-care testing, AI-driven diagnostics, and strategic partnerships presents lucrative growth opportunities in the monkeypox testing market.
Point-of-care (PoC) testing is on the rise because it can offer decentralized and rapid testing, taking the load off conventional laboratories. Portable PCR and lateral flow assays provide room for real-time diagnostics at clinics, airports, and rural health centers, making it more accessible. Integration of AI and machine learning in diagnostics is another area with great potential. Cepheid and Abbott are among the companies investing in AI-based test platforms that can automate result interpretation, eliminate human error, and enhance efficiency. AI-based diagnostics can read thousands of test results in seconds, enhancing outbreak surveillance. Strategic collaborations among government agencies, biotech companies, and healthcare organizations are speeding up innovation. For instance, the Bill & Melinda Gates Foundation collaborated with several diagnostic companies to create affordable monkeypox testing solutions for underserved areas. Increasing public-private partnerships will propel cost-effective solutions and regulatory clearances. Additionally, the growing emphasis on home use and self-testing kits provides an unexploited market sector. Businesses are developing at-home monkeypox testing kits, comparable to rapid COVID-19 tests, with convenience and discretion. Rolling out these innovations worldwide could revolutionize accessibility to testing, particularly among areas with poor healthcare infrastructure.
Challenges
The monkeypox testing market faces supply chain disruptions, the risk of false negatives, and global healthcare inequalities, limiting its rapid expansion.
The lack of essential diagnostic materials, such as PCR reagents and test kits, has resulted in bottlenecks in the availability of tests. Disruptions in global supply chains due to geopolitical tensions and raw material shortages have raised production costs by 20-30%, which has made affordable diagnostics more difficult to attain. Another issue is false negatives, most notably for lateral flow assays (LFA). As LFA offers rapid results, its sensitivity is lower than PCR, and thus it misses cases and delays treatment. LFA tests, under real-world conditions, have reported false-negative rates of 15-20%, which makes the reliability of LFA questionable. This then restricts reliance on rapid diagnostic tools, hindering their extensive use. Moreover, global health disparities continue to pose a major hindrance. Low-income nations, especially those in Africa and some regions of Asia, have few facilities for testing, trained personnel, and government support. As high-income countries scale up testing, disadvantaged communities lack resources to make mass diagnostics a reality, and this results in late outbreak responses.
By Technology
Polymerase Chain Reaction (PCR) led the monkeypox testing market in 2023 with a 68.5% share of the overall market. PCR was the gold standard because it is highly accurate, specific, and can detect diseases early. The demand increased as governments and healthcare institutions gave high priority to molecular diagnostics for exact identification, particularly during outbreaks. The extensive presence of PCR facilities in hospitals and laboratories further reinforced its dominant position.
Lateral Flow Assay (LFA) is the most rapidly expanding technology segment due to its low cost, simplicity, and short turnaround time. With the growing demand for point-of-care testing and decentralized diagnosis, LFA has been popular in resource-poor environments and emergency testing applications. Public health efforts to increase monkeypox surveillance in underserved areas are also boosting its growth.
By End-use
Diagnostic laboratories dominated the market in 2023, with 52.3% of the overall market share. This leadership was fueled by the dependence on centralized laboratory testing, especially PCR-based diagnostics, which needs sophisticated infrastructure and skilled personnel. Governments and healthcare organizations favored laboratory-based testing for precision and epidemiological monitoring, cementing its dominance.
Hospitals & Clinics represent the most rapidly growing end-use segment, driven by the rapid adoption of rapid diagnostics at the point of care. The need to deliver on-the-spot testing and treatment information has prompted hospital-based monkeypox testing, particularly in infectious disease and emergency units. Enhanced access to rapid molecular testing as well as increasing numbers of suspected cases have fueled this segment's growth even more.
North America held the largest share in the monkeypox testing market in 2023 at 41.2% of the total global market share. The region's high rate of testing established healthcare systems, and robust government programs to stem the epidemic were responsible for its dominance. The United States accounted for the lion's share within the region, with the CDC and FDA being actively involved in the expansion of monkeypox testing, such as PCR and point-of-care tests. Major diagnostic companies' presence and extensive public awareness accelerated market growth.
Europe was close to following, as it had substantial government-sponsored programs of testing and high rates of uptake of the latest diagnostic tools. The UK, Germany, and France registered high volumes of testing, particularly in hospitals and public health labs.
The Asia-Pacific region is the fastest-growing market, expected to grow at a significant rate with growing investments in healthcare infrastructure, growing cases, and better access to diagnostic equipment. The lead is taken by China, India, and Japan, whose governments are strengthening laboratory capacity and point-of-care testing accessibility. Africa is also another critical focus area because of endemic outbreaks and global organizations are expanding funding for low-cost rapid testing solutions to enhance disease surveillance and control.
Aegis Sciences Corporation
BD (Becton, Dickinson, and Company)
Chembio Diagnostics Inc.
Laboratory Corporation of America Holdings (LabCorp)
Mayo Clinic Laboratories
QIAGEN
Quest Diagnostics Inc.
Sonia Healthcare Ltd
Sonora Quest Laboratories
Thermo Fisher Scientific
In Aug 2024, Siemens developed an indigenous Monkeypox RT-PCR testing kit for India, which has received approval from the Central Drugs Standard Control Organisation (CDSCO). This marks a significant step in strengthening India's diagnostic capabilities against Monkeypox.
| Report Attributes | Details |
|---|---|
| Market Size in 2023 | USD 1.73 billion |
| Market Size by 2032 | USD 2.58 billion |
| CAGR | CAGR of 4.55% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Technology [Polymerase chain reaction (PCR), Lateral Flow Assay (LFA), Others] • By End-use [Hospitals & Clinics, Diagnostics Laboratories, Others] |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
| Company Profiles | Aegis Sciences Corporation, BD (Becton, Dickinson and Company), Chembio Diagnostics Inc., Laboratory Corporation of America Holdings (LabCorp), Mayo Clinic Laboratories, QIAGEN, Quest Diagnostics Inc., Sonia Healthcare Ltd, Sonora Quest Laboratories, Thermo Fisher Scientific. |
Ans: The market is expected to grow at a compound annual growth rate (CAGR) of 4.55% during the forecast period.
Ans: The Monkeypox Testing market is predicted to reach a valuation of USD 2.58 billion by 2032, increasing from USD 1.73 billion in 2023.
Ans: The monkeypox testing market is driven by rising global monkeypox cases, increased government funding, and advancements in diagnostic technologies.
Ans: The market faces high costs of PCR-based testing, limited accessibility in low-income regions, and stringent regulatory requirements.
Ans: North America dominates the Monkeypox Testing market.
Table of content
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.2 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Monkeypox Testing Adoption Rate (2023-2032), by Region
5.2 Monkeypox Testing Reimbursement and Insurance Coverage (2023-2032)
5.3 Regulatory Landscape and Approval Trends (2023-2032)
5.4 Public Health Initiatives and Government Response (2023-2032)
5.5 Emerging Innovations in Monkeypox Testing (2023-2032)
5.6 Laboratory vs. Point-of-Care (PoC) Testing Trends (2023-2032)
5.7 Healthcare Spending on Monkeypox Testing, by Region (Government, Commercial, Private, Out-of-Pocket) – 2023
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Service Benchmarking
6.3.1 Service specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new Service launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Monkeypox Testing Market Segmentation, by Technology
7.2 Polymerase chain reaction (PCR)
7.2.1 Polymerase chain reaction (PCR) Market Trends Analysis (2020-2032)
7.2.2 Polymerase chain reaction (PCR) Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Lateral Flow Assay (LFA)
7.3.1 Lateral Flow Assay (LFA) Market Trends Analysis (2020-2032)
7.3.2 Lateral Flow Assay (LFA) Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 Others
7.4.1 Others Market Trends Analysis (2020-2032)
7.4.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Monkeypox Testing Market Segmentation, by End-use
8.2 Hospitals & Clinics
8.2.1 Hospitals & Clinics Market Trends Analysis (2020-2032)
8.2.2 Hospitals & Clinics Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Diagnostics Laboratories
8.3.1 Diagnostics Laboratories Market Trends Analysis (2020-2032)
8.3.2 Diagnostics Laboratories Market Size Estimates and Forecasts to 2032 (USD Billion)
8.4 Others
8.4.1 Others Market Trends Analysis (2020-2032)
8.4.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Regional Analysis
9.1 Chapter Overview
9.2 North America
9.2.1 Trends Analysis
9.2.2 North America Monkeypox Testing Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.2.3 North America Monkeypox Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.2.4 North America Monkeypox Testing Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.2.5 USA
9.2.5.1 USA Monkeypox Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.2.5.2 USA Monkeypox Testing Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.2.6 Canada
9.2.6.1 Canada Monkeypox Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.2.6.2 Canada Monkeypox Testing Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.2.7 Mexico
9.2.7.1 Mexico Monkeypox Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.2.7.2 Mexico Monkeypox Testing Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.3 Europe
9.3.1 Eastern Europe
9.3.1.1 Trends Analysis
9.3.1.2 Eastern Europe Monkeypox Testing Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.3.1.3 Eastern Europe Monkeypox Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.3.1.4 Eastern Europe Monkeypox Testing Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.3.1.5 Poland
9.3.1.5.1 Poland Monkeypox Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.3.1.5.2 Poland Monkeypox Testing Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.3.1.6 Romania
9.3.1.6.1 Romania Monkeypox Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.3.1.6.2 Romania Monkeypox Testing Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.3.1.7 Hungary
9.3.1.7.1 Hungary Monkeypox Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.3.1.7.2 Hungary Monkeypox Testing Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.3.1.8 Turkey
9.3.1.8.1 Turkey Monkeypox Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.3.1.8.2 Turkey Monkeypox Testing Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.3.1.9 Rest of Eastern Europe
9.3.1.9.1 Rest of Eastern Europe Monkeypox Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.3.1.9.2 Rest of Eastern Europe Monkeypox Testing Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.3.2 Western Europe
9.3.2.1 Trends Analysis
9.3.2.2 Western Europe Monkeypox Testing Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.3.2.3 Western Europe Monkeypox Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.3.2.4 Western Europe Monkeypox Testing Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.3.2.5 Germany
9.3.2.5.1 Germany Monkeypox Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.3.2.5.2 Germany Monkeypox Testing Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.3.2.6 France
9.3.2.6.1 France Monkeypox Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.3.2.6.2 France Monkeypox Testing Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.3.2.7 UK
9.3.2.7.1 UK Monkeypox Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.3.2.7.2 UK Monkeypox Testing Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.3.2.8 Italy
9.3.2.8.1 Italy Monkeypox Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.3.2.8.2 Italy Monkeypox Testing Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.3.2.9 Spain
9.3.2.9.1 Spain Monkeypox Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.3.2.9.2 Spain Monkeypox Testing Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.3.2.10 Netherlands
9.3.2.10.1 Netherlands Monkeypox Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.3.2.10.2 Netherlands Monkeypox Testing Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.3.2.11 Switzerland
9.3.2.11.1 Switzerland Monkeypox Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.3.2.11.2 Switzerland Monkeypox Testing Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.3.2.12 Austria
9.3.2.12.1 Austria Monkeypox Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.3.2.12.2 Austria Monkeypox Testing Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.3.2.13 Rest of Western Europe
9.3.2.13.1 Rest of Western Europe Monkeypox Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.3.2.13.2 Rest of Western Europe Monkeypox Testing Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.4 Asia Pacific
9.4.1 Trends Analysis
9.4.2 Asia Pacific Monkeypox Testing Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.4.3 Asia Pacific Monkeypox Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.4.4 Asia Pacific Monkeypox Testing Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.4.5 China
9.4.5.1 China Monkeypox Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.4.5.2 China Monkeypox Testing Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.4.6 India
9.4.5.1 India Monkeypox Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.4.5.2 India Monkeypox Testing Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.4.5 Japan
9.4.5.1 Japan Monkeypox Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.4.5.2 Japan Monkeypox Testing Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.4.6 South Korea
9.4.6.1 South Korea Monkeypox Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.4.6.2 South Korea Monkeypox Testing Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.4.7 Vietnam
9.4.7.1 Vietnam Monkeypox Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.2.7.2 Vietnam Monkeypox Testing Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.4.8 Singapore
9.4.8.1 Singapore Monkeypox Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.4.8.2 Singapore Monkeypox Testing Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.4.9 Australia
9.4.9.1 Australia Monkeypox Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.4.9.2 Australia Monkeypox Testing Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.4.10 Rest of Asia Pacific
9.4.10.1 Rest of Asia Pacific Monkeypox Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.4.10.2 Rest of Asia Pacific Monkeypox Testing Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.5 Middle East and Africa
9.5.1 Middle East
9.5.1.1 Trends Analysis
9.5.1.2 Middle East Monkeypox Testing Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.5.1.3 Middle East Monkeypox Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.5.1.4 Middle East Monkeypox Testing Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.5.1.5 UAE
9.5.1.5.1 UAE Monkeypox Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.5.1.5.2 UAE Monkeypox Testing Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.5.1.6 Egypt
9.5.1.6.1 Egypt Monkeypox Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.5.1.6.2 Egypt Monkeypox Testing Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.5.1.7 Saudi Arabia
9.5.1.7.1 Saudi Arabia Monkeypox Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.5.1.7.2 Saudi Arabia Monkeypox Testing Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.5.1.8 Qatar
9.5.1.8.1 Qatar Monkeypox Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.5.1.8.2 Qatar Monkeypox Testing Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.5.1.9 Rest of Middle East
9.5.1.9.1 Rest of Middle East Monkeypox Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.5.1.9.2 Rest of Middle East Monkeypox Testing Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.5.2 Africa
9.5.2.1 Trends Analysis
9.5.2.2 Africa Monkeypox Testing Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.5.2.3 Africa Monkeypox Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.5.2.4 Africa Monkeypox Testing Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.5.2.5 South Africa
9.5.2.5.1 South Africa Monkeypox Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.5.2.5.2 South Africa Monkeypox Testing Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.5.2.6 Nigeria
9.5.2.6.1 Nigeria Monkeypox Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.5.2.6.2 Nigeria Monkeypox Testing Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.6 Latin America
9.6.1 Trends Analysis
9.6.2 Latin America Monkeypox Testing Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.6.3 Latin America Monkeypox Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.6.4 Latin America Monkeypox Testing Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.6.5 Brazil
9.6.5.1 Brazil Monkeypox Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.6.5.2 Brazil Monkeypox Testing Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.6.6 Argentina
9.6.6.1 Argentina Monkeypox Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.6.6.2 Argentina Monkeypox Testing Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.6.7 Colombia
9.6.7.1 Colombia Monkeypox Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.6.7.2 Colombia Monkeypox Testing Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
9.6.8 Rest of Latin America
9.6.8.1 Rest of Latin America Monkeypox Testing Market Estimates and Forecasts, by Technology (2020-2032) (USD Billion)
9.6.8.2 Rest of Latin America Monkeypox Testing Market Estimates and Forecasts, by End-use (2020-2032) (USD Billion)
10. Company Profiles
10.1 Aegis Sciences Corporation
10.1.1 Company Overview
10.1.2 Financial
10.1.3 Products/ Services Offered
10.1.4 SWOT Analysis
10.2 BD (Becton, Dickinson, and Company)
10.2.1 Company Overview
10.2.2 Financial
10.2.3 Products/ Services Offered
10.2.4 SWOT Analysis
10.3 Chembio Diagnostics Inc.
10.3.1 Company Overview
10.3.2 Financial
10.3.3 Products/ Services Offered
10.3.4 SWOT Analysis
10.4 Laboratory Corporation of America Holdings (LabCorp)
10.4.1 Company Overview
10.4.2 Financial
10.4.3 Products/ Services Offered
10.4.4 SWOT Analysis
10.5 Mayo Clinic Laboratories
10.5.1 Company Overview
10.5.2 Financial
10.5.3 Products/ Services Offered
10.5.4 SWOT Analysis
10.6 QIAGEN
10.6.1 Company Overview
10.6.2 Financial
10.6.3 Products/ Services Offered
10.6.4 SWOT Analysis
10.7 Quest Diagnostics Inc.
10.7.1 Company Overview
10.7.2 Financial
10.7.3 Products/ Services Offered
10.7.4 SWOT Analysis
10.8 Sonia Healthcare Ltd
10.8.1 Company Overview
10.8.2 Financial
10.8.3 Products/ Services Offered
10.8.4 SWOT Analysis
10.9 Sonora Quest Laboratories
10.9.1 Company Overview
10.9.2 Financial
10.9.3 Products/ Services Offered
10.9.4 SWOT Analysis
10.10 Thermo Fisher Scientific
10.10.1 Company Overview
10.10.2 Financial
10.10.3 Products/ Services Offered
10.10.4 SWOT Analysis
11. Use Cases and Best Practices
12. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segments
By Technology
Polymerase chain reaction (PCR)
Lateral Flow Assay (LFA)
Others
By End-use
Hospitals & Clinics
Diagnostics Laboratories
Others
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Detailed Volume Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Competitive Product Benchmarking
Geographic Analysis
Additional countries in any of the regions
Customized Data Representation
Detailed analysis and profiling of additional market players
The Post-traumatic stress disorder treatment Market was valued at USD 15.00 Bn in 2023 and is expected to reach USD 22.85 Bn by 2032, growing at a CAGR of 4.81% from 2024-2032.
The NGS based RNA Sequencing Market Size was USD 2.9 Billion in 2023 and will reach USD 12.1 Billion by 2032 and grow at a CAGR of 17.1% Over the Forecast Period of 2024-2032.
The Subcutaneous Drug Delivery Devices Market was worth USD 30.92 billion in 2023 and is predicted to be worth USD 56.95 billion by 2032, growing at a CAGR of 7.07% between 2024 and 2032.
Epilepsy Drugs Market was valued at USD 7.6 billion in 2023 and is expected to reach USD 10.9 billion by 2032, growing at a CAGR of 4.06% from 2024-2032.
Surgical Imaging Market was valued at USD 148 billion in 2023 and is expected to reach USD 340.5 billion by 2032 and grow at a CAGR of 9.7% from 2024 to 2032.
The Epilepsy Surgery Market Size was valued at USD 1.20 billion in 2023 and is expected to reach USD 2.00 billion by 2032 and grow at a CAGR of 5.87% over the forecast period 2024-2032.
Hi! Click one of our member below to chat on Phone
© 2025 All Rights Reserved by SNS Insider Pvt Ltd
